We’re presenting a Phase Ib study looking at R-CHOP in combination with two very cool drugs, cereblon modifiers called CC-220, or iberdomide, or CC-99282. So, the patients are not getting both of those drugs. Instead, half the patients are getting 99282, half of them getting iberdomide, and all patients are getting R-CHOP. These cereblon-targeting drugs are the new version of lenalidomide and they have incredible promise...
We’re presenting a Phase Ib study looking at R-CHOP in combination with two very cool drugs, cereblon modifiers called CC-220, or iberdomide, or CC-99282. So, the patients are not getting both of those drugs. Instead, half the patients are getting 99282, half of them getting iberdomide, and all patients are getting R-CHOP. These cereblon-targeting drugs are the new version of lenalidomide and they have incredible promise. In single-agent trials in the past, they’ve shown very good response rates, and in combination with R-CHOP thus far, we’re seeing some impressive results. At this ASH Trials-in-Progress poster, we’re not yet presenting any data, but the study is open and accruing very well, and we’re hoping to see future studies combining cereblon agents and R-CHOP in the frontline setting.